June 18, 2020 / 1:43 PM / a month ago

BRIEF-Pfizer, Sangamo Therapeutics Announce Data From Phase 1/2 Alta Study Of Giroctocogene Fitelparvovec

June 18 (Reuters) -

* PFIZER, SANGAMO THERAPEUTICS ANNOUNCED UPDATED FOLLOW-UP DATA FROM PHASE 1/2 ALTA STUDY OF GIROCTOCOGENE FITELPARVOVEC

* PFIZER - ALL 5 PATIENTS WITH SEVERE HEMOPHILIA A WHO GOT 3E13 VG/KG DOSE SHOWED SUSTAINED FACTOR VIII ACTIVITY LEVELS, WITH MEDIAN 64.2% VIA CHROMOGENIC ASSAY

* PFIZER - GIROCTOCOGENE FITELPARVOVEC WAS GENERALLY WELL TOLERATED

* PFIZER - NO PATIENTS EXPERIENCED BLEEDING EVENTS OR REQUIRED FVIII INFUSIONS

* PFIZER - DATA ARE BEING PRESENTED AS LATE-BREAKING ORAL ABSTRACT AT WORLD FEDERATION OF HEMOPHILIA 2020 WORLD CONGRESS

* PFIZER - TO PRESENT FURTHER FOLLOW-UP DATA FROM ALTA STUDY WHEN ALL 5 PATIENTS IN 3E13 VG/KG DOSE COHORT HAVE BEEN FOLLOWED FOR AT LEAST 1 YEAR Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below